Opnol (Dexamethasone Sodium Phosphate)

Dexamethasone sodium phosphate binds to glucocorticoid receptors inside cells, forming a complex that enters the nucleus and influences gene expression. This process suppresses the production of inflammatory cytokines, stabilises cell membranes, and reduces immune cell activity, leading to decreased swelling, pain, and immune‑mediated damage.

The dosage of Opnol is determined by the prescribing clinician based on the specific indication, patient weight, severity of the condition, and response to therapy. Healthcare professionals calculate the appropriate amount and administration schedule for each individual case.

Dexamethasone crosses the placenta and may affect fetal development, so it should only be used in pregnancy when the potential benefit outweighs the risk. It is excreted in breast milk; therefore, caution is advised for nursing mothers, and a healthcare provider should evaluate the need for treatment.

To request Opnol, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, confirming trade or institutional credentials before providing pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Opnol delivers dexamethasone sodium phosphate, a potent, long‑acting corticosteroid with high anti‑inflammatory potency. Compared with agents like prednisone or methylprednisolone, dexamethasone has a longer half‑life and stronger glucocorticoid activity, allowing less frequent dosing but requiring careful monitoring for systemic side effects.

Opnol should be stored at 2‑8 °C (refrigerated). Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking the solution. If the product reaches room temperature, use it promptly and do not return it to the refrigerator.

Opnol is supplied as a sterile injectable solution for intravenous (IV) administration. It is typically given by a healthcare professional through a controlled IV infusion or bolus, following the dosage and rate prescribed by the treating physician.

Serious risks include adrenal suppression leading to cortisol deficiency, severe hypersensitivity reactions such as anaphylaxis, opportunistic infections due to immune suppression, and rare events like osteonecrosis of the jaw or thromboembolic complications. Patients should be monitored closely for these outcomes.

Opnol is contraindicated in patients with known hypersensitivity to dexamethasone or any component of the formulation. It should be avoided in individuals with systemic fungal infections, uncontrolled viral infections, or those receiving live vaccines unless the benefits clearly outweigh the risks.